WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 414665
CAS#: 26020-55-3 (free base)
Description: Oxetorone Free Base is used in the treatment of migraine.
MedKoo Cat#: 414665
Name: Oxetorone Free Base
CAS#: 26020-55-3 (free base)
Chemical Formula: C21H21NO2
Exact Mass: 319.1572
Molecular Weight: 319.4
Elemental Analysis: C, 78.97; H, 6.63; N, 4.39; O, 10.02
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 26020-55-3 (free base); 34522-46-8 (fumarate)
Synonym: Oxetorone Free Base; Oxetorona; Oxetoronum
IUPAC/Chemical Name: 3-(12H-Benzofuro(3,2-c)(1)benzoxepin-6-yliden)-N,N-dimethylpropylamin
InChi Key: VZVRZTZPHOHSCK-LICLKQGHSA-N
InChi Code: InChI=1S/C21H21NO2/c1-22(2)13-7-10-17-15-8-3-5-11-19(15)23-14-18-16-9-4-6-12-20(16)24-21(17)18/h3-6,8-12H,7,13-14H2,1-2H3/b17-10+
SMILES Code: CN(C)CC/C=C1C(OC2=CC=CC=C23)=C3COC4=CC=CC=C/14
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 319.4 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Macaigne G, Boivin JF, Chayette C, Cheaib S, Deplus R. Colite lymphocytaire associée à la prise d'oxétorone [Oxetorone-associated lymphocytic colitis]. Gastroenterol Clin Biol. 2002 May;26(5):537. French. PMID: 12122372.
2: Deguigne M, Bruneau C, Touré A, Turcant A, Le Roux G. New evidence for oxetorone toxicity. Clin Toxicol (Phila). 2017 Feb;55(2):142-146. doi: 10.1080/15563650.2016.1267358. Epub 2016 Dec 14. PMID: 27967233.
3: Pradalier A, Molitor JL, Campinos C. Oxétorone et sueurs profuses [Oxetorone and profuse sweating]. Therapie. 2003 Mar-Apr;58(2):166-7. French. doi: 10.2515/therapie:2003025. PMID: 12942859.
4: Payen C, Patat AM, Pulce C, Descotes J. Intoxication aiguë par oxetorone [Acute poisoning with oxetorone]. Therapie. 2006 Nov-Dec;61(6):548-50. French. doi: 10.2515/therapie:2006081. PMID: 17348615.
5: Pradalier A. Hyperprolactinaemia and depression induced by oxetorone. Cephalalgia. 1996 Dec;16(8):560-1. doi: 10.1046/j.1468-2982.1996.1608560.x. PMID: 8980859.
6: Fathallah N, Chatti S, Azouz MM. Colite lymphocytaire associée à la prise d'oxétorone [Lymphocytic colitis associated with oxetorone consumption]. Gastroenterol Clin Biol. 2010 Feb;34(2):154-5. French. doi: 10.1016/j.gcb.2009.12.001. Epub 2010 Jan 21. PMID: 20096517.
7: Galerneau V, Petit J, Deghmani M, Leroy J, Droy JM, Leroy A, Oksenhendler G, Winckler C. Severe self-poisoning with oxetorone: report of one case. J Toxicol Clin Toxicol. 1990;28(1):111-6. doi: 10.3109/15563659008993482. PMID: 2381017.
8: Roos C. Migraine : données épidémiologiques, cliniques et thérapeutiques [Migraine epidemiological, clinical and therapeutic data]. Biol Aujourdhui. 2019;213(1-2):35-41. French. doi: 10.1051/jbio/2019019. Epub 2019 Jul 5. PMID: 31274101.
9: Barchewitz G, Vernant C, Mazue G, Binon F, Cier A, Tuchmann Duplessis H. Oxetorone-induced hyperprogesteronemia and the development of uterine decidual lesions in rats. Arzneimittelforschung. 1984;34(9):1007-10. PMID: 6542368.
10: de Coster J. Etude de l'oxétorone dans les céphalées migraineuses [Oxetorone in the treatment of migrainous cephalalgia (author's transl)]. Schweiz Rundsch Med Prax. 1976 Jul 13;65(28):879-82. French. PMID: 1005299.
